<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05092698</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-VIT</org_study_id>
    <nct_id>NCT05092698</nct_id>
  </id_info>
  <brief_title>The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19</brief_title>
  <acronym>COVID-VIT</acronym>
  <official_title>The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the successful treatment of patients with moderate coronavirus disease 2019&#xD;
      (COVID-19), outcomes for patients with severe disease remain unsatisfactory. In this category&#xD;
      of patients, the course of the disease is complicated by the development of acute respiratory&#xD;
      distress syndrome (ARDS) and the need for mechanical ventilation in the intensive care unit&#xD;
      (ICU). Mortality in this category of patients reaches 85%. The lack of effective treatment&#xD;
      for COVID-19 has prompted scientists to look for new strategies to reduce the incidence and&#xD;
      severity of COVID-19, disease progression, and mortality.&#xD;
&#xD;
      Disease severity and mortality rates due to COVID-19 infection are greater in the elderly and&#xD;
      chronically ill patients, populations at high risk for vitamin D deficiency. Vitamin D plays&#xD;
      an important role in immune function and inflammation.&#xD;
&#xD;
      A number of experimental studies have shown that stimulation of vitamin D receptors can&#xD;
      improve the course of ARDS due to inhibition of the hyperimmune inflammatory response,&#xD;
      regulation of the renin-angiotensin system, modulation of neutrophil activity, maintenance of&#xD;
      the integrity of the pulmonary epithelial barrier and stimulation of epithelial repair, as&#xD;
      well as by reducing hypercoagulation.&#xD;
&#xD;
      Several studies on ICU patients have reported that low vitamin D (25(OH)D) concentrations are&#xD;
      associated with a higher risk of negative outcomes such as death, organ failure, prolonged&#xD;
      mechanical ventilation, a higher rate of ventilation-associated pneumonia, and sepsis.&#xD;
&#xD;
      While the available evidence to-date, from largely poor-quality observational studies, may be&#xD;
      viewed as showing a trend for an association between low serum 25(OH)D levels and COVID-19&#xD;
      related health outcomes, this relationship was not found to be statistically significant.&#xD;
      Calcifediol supplementation may have a protective effect on COVID-19 related ICU admissions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the efficacy of vitamin D (cholecalciferol)&#xD;
      supplementation in patients with severe and extremely severe disease caused by the SARS-CoV-2&#xD;
      virus, admitted to an ICU of the COVID-center on the first day and in dynamics until&#xD;
      discharge from the hospital or death. Patients with vitamin D deficiency [25-hydroxyvitamin D&#xD;
      (25(OH)D) ≤ 30 ng/ml] will be randomized to two groups: 1 - patients will receive 60,000 IU&#xD;
      of cholecalciferol supplementation; 2 - patients will receive matched placebo.&#xD;
&#xD;
      The demographic and clinical data will be collected. Laboratory data (hemoglobin,&#xD;
      lymphocytes, neutrophil to lymphocyte ratio, D-dimer level, Interleukin-6, procalcitonin,&#xD;
      ferritin, glucose level, high-sensitive troponin Т, vitamin D level (25(OH)D), acid-base&#xD;
      balance, signs of a secondary bacterial infection, immunogram, Von Willebrand factor antigen&#xD;
      and Instrumental data (CT-scan, Electrocardiography, echocardiography, arterial and venous&#xD;
      ultrasound investigation) will be analysed. The frequency of complications, duration of&#xD;
      mechanical ventilation, length of stay in the ICU and in the hospital, and mortality will be&#xD;
      evaluated.&#xD;
&#xD;
      This study is single-centre prospective randomized placebo-controlled trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Сomplete blood count</measure>
    <time_frame>Change from baseline on day 5 during ICU treatment</time_frame>
    <description>Сomplete blood count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Сomplete blood count dynamics 1</measure>
    <time_frame>Change from baseline on day 10 during ICU treatment</time_frame>
    <description>Сomplete blood count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Сomplete blood count dynamics 2</measure>
    <time_frame>Change from baseline on day 15 during ICU treatment</time_frame>
    <description>Сomplete blood count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Сomplete blood count dynamics 3</measure>
    <time_frame>Change from baseline on day 21 during ICU treatment</time_frame>
    <description>Сomplete blood count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Change from baseline on day 5 during ICU treatment</time_frame>
    <description>C-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein 1</measure>
    <time_frame>Change from baseline on day 10 during ICU treatment</time_frame>
    <description>C-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein 2</measure>
    <time_frame>Change from baseline on day 15 during ICU treatment</time_frame>
    <description>C-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein 3</measure>
    <time_frame>Change from baseline on day 21 during ICU treatment</time_frame>
    <description>C-reactive protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Von Willebrand factor antigen</measure>
    <time_frame>Change from baseline on day 7 during ICU treatment</time_frame>
    <description>Von Willebrand factor antigen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombotic complications</measure>
    <time_frame>60 days</time_frame>
    <description>Arterial or venous thrombotic complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogram</measure>
    <time_frame>Change from baseline on day 7 during ICU treatment</time_frame>
    <description>The amount of NKT cells (CD3+CD56+CD16+), NK cells (CD3-CD56+CD16+)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proinflammatory marker</measure>
    <time_frame>Change from baseline on day 5 during ICU treatment</time_frame>
    <description>D-dimer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proinflammatory marker 1</measure>
    <time_frame>on day 10 during ICU treatment</time_frame>
    <description>D-dimer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proinflammatory marker 2</measure>
    <time_frame>on day 15 during ICU treatment</time_frame>
    <description>D-dimer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proinflammatory marker 3</measure>
    <time_frame>on day 21 during ICU treatment</time_frame>
    <description>D-dimer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory marker</measure>
    <time_frame>Change from baseline on day 5 during ICU treatment</time_frame>
    <description>Interleukin-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory marker 1</measure>
    <time_frame>Change from baseline on day 10 during ICU treatment</time_frame>
    <description>Interleukin-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory marker 2</measure>
    <time_frame>Change from baseline on day 15 during ICU treatment</time_frame>
    <description>Interleukin-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory marker 3</measure>
    <time_frame>Change from baseline on day 21 during ICU treatment</time_frame>
    <description>Interleukin-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infection marker</measure>
    <time_frame>Change from baseline on day 5 during ICU treatment</time_frame>
    <description>Procalcitonin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infection marker 1</measure>
    <time_frame>Change from baseline on day 10 during ICU treatment</time_frame>
    <description>Procalcitonin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>60 days</time_frame>
    <description>The dead and survived patients ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation duration</measure>
    <time_frame>30 days</time_frame>
    <description>The amount of mechanical ventilation days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive Mechanical ventilation duration</measure>
    <time_frame>30 days</time_frame>
    <description>The amount of Non-invasive mechanical ventilation days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the ICU</measure>
    <time_frame>60 days</time_frame>
    <description>The amount of day of ICU treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital</measure>
    <time_frame>60 days</time_frame>
    <description>The amount of day of hospital treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection complications</measure>
    <time_frame>60 day</time_frame>
    <description>The amount of Infection complications</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>Vit_D_suppl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube followed by 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil weekly until discharge or death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vit_D_placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive 45 ml of herbal oil orally or via feeding tube followed by 45 ml of herbal oil weekly until discharge or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (cholecalciferol)</intervention_name>
    <description>Patients will receive either 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil or matched placebo orally or via feeding tube after serum Vitamin D concentrations measurement followed by either the same dose of cholecalciferol or 45 ml of pure herbal oil weekly until discharge or death.</description>
    <arm_group_label>Vit_D_placebo</arm_group_label>
    <arm_group_label>Vit_D_suppl</arm_group_label>
    <other_name>herbal oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all patients with COVID-19 admitted to the ICU with vitamin D deficiency&#xD;
             [25-hydroxyvitamin D (25(OH)D) ≤ 30 ng/ml]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 24 hours in ICU by any reason&#xD;
&#xD;
          -  chronic decompensated disease with extrapulmonary organ dysfunction (tumour&#xD;
             progression, liver cirrhosis, congestive heart failure) with a life expectancy of less&#xD;
             than 48 hours&#xD;
&#xD;
          -  atonic coma&#xD;
&#xD;
          -  allergic reaction on cholecalciferol or herbal oil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatiana V Klypa, ScD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal Research Clinical Center of Federal Medical &amp; Biological Agency</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikhail V Bychinin, PhD</last_name>
    <phone>+7 926 217-99-72</phone>
    <email>drbychinin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irina A Mandel, PhD</last_name>
    <phone>+79039528337</phone>
    <email>irina.a.mandel@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal Research Clinical Center of Federal Medical &amp; Biological Agency</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail V Bychinin, PhD</last_name>
      <phone>+7 926 217-99-72</phone>
      <email>drbychinin@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Irina A Mandel, PhD</last_name>
      <phone>+79039528337</phone>
      <email>irina.a.mandel@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Bassatne A, Basbous M, Chakhtoura M, El Zein O, Rahme M, El-Hajj Fuleihan G. The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis. Metabolism. 2021 Jun;119:154753. doi: 10.1016/j.metabol.2021.154753. Epub 2021 Mar 24.</citation>
    <PMID>33774074</PMID>
  </reference>
  <reference>
    <citation>Bychinin MV, Klypa TV, Mandel IA, Andreichenko SA, Baklaushev VP, Yusubalieva GM, Kolyshkina NA, Troitsky AV. Low Circulating Vitamin D in Intensive Care Unit-Admitted COVID-19 Patients as a Predictor of Negative Outcomes. J Nutr. 2021 Aug 7;151(8):2199-2205. doi: 10.1093/jn/nxab107.</citation>
    <PMID>33982128</PMID>
  </reference>
  <reference>
    <citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.</citation>
    <PMID>32109013</PMID>
  </reference>
  <reference>
    <citation>Kong J, Zhu X, Shi Y, Liu T, Chen Y, Bhan I, Zhao Q, Thadhani R, Li YC. VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system. Mol Endocrinol. 2013 Dec;27(12):2116-25. doi: 10.1210/me.2013-1146. Epub 2013 Nov 6.</citation>
    <PMID>24196349</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)</keyword>
  <keyword>coronavirus disease 2019 (COVID-19)</keyword>
  <keyword>severe and extremely severe disease</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

